Study wrapper · #218
Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.
Editor's note
Medicinal-chemistry work, not a biological or clinical study: the researchers built hybrid molecules combining structural features of NN703 and ipamorelin, aiming for more potent growth-hormone secretagogues. Testing a series of NN703 analogues — with lysine-mimetic groups and naphthyl- or biphenylalanine cores — in a rat pituitary-cell assay and then in single-dose pig experiments, they found that re-adding certain pharmacophore groups previously stripped out during oral-bioavailability optimisation yielded unexpectedly potent compounds both in vitro and in vivo. Ipamorelin serves here as a design template, not as the compound under investigation. For readers focused on ipamorelin, this offers only narrow context: it places the peptide within an ongoing effort to engineer stronger, orally viable secretagogues. There are no human data, no clinical endpoints, and no safety information for people — just cell assays and a single pig dose. Treat it as chemistry; human studies would be required for any therapeutic conclusion about these compounds or ipamorelin.
Plain-language abstract
This is a drug-design (chemistry) study aimed at creating stronger compounds that make the body release growth hormone. The researchers combined structural pieces of two known growth-hormone-releasing compounds, NN703 and ipamorelin, to make a series of hybrid molecules. These carried building blocks that mimic the amino acid lysine, paired with bulky chemical groups (naphthyl- or biphenylalanine) at their core. Each new compound was tested first in a laboratory assay using rat pituitary cells, then in pigs at a single dose. The team found that adding back certain chemical groups — ones that had earlier been removed to improve absorption by mouth — made the compounds unexpectedly potent, both in the cell tests and in the live pig experiments. Ipamorelin was used as a starting template for the design rather than as the compound being studied. This is early laboratory and animal chemistry work; it does not test whether ipamorelin or the new hybrids benefit or harm people, and reports no human results or side effects.